Tycel Phillips, M.D.

800-826-4673
Tycel Phillips, M.D.
Hematologist-Oncologist
Clinical Expertise
Hematology
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Lymphoma
Research Area
Hematology and Hematopoietic Cell Transplantation
Appointments
Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

Cancer care is a sort of personal mission for Tycel Phillips, M.D.

As a teen, he saw how pancreatic cancer affected his grandmother and decided to follow her example of service and make his career helping others as a physician. When he was a medical resident, he lost his mother to breast cancer; her experience with chemotherapy inspired him to pursue research into treatments that are less toxic for patients.

His approach to patients is to listen first to understand their needs and develop the most beneficial treatment plan.

Dr. Phillips earned his medical degree from Rush University, followed by a residency in internal medicine at the John H. Stroger Jr. Hospital of Cook County in Chicago. His fellowship training in oncology/hematology took place at University Hospitals in Cleveland. Before joining City of Hope, he was a clinical associate professor at the University of Michigan, where he was appointed the Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation.

Leading clinical trials into new targeted therapies is a vital part of Dr. Phillips’ work. He has published over 40 peer-reviewed studies and attracted dozens of research grants.

Away from work, Dr. Phillips likes to read, ride his bicycle with his children, exercise and travel.

Location
Education & Experience
Board Certifications
  • American Board of Internal Medicine-Medical Oncology
  • American Board of Internal Medicine-Hematology
Degrees
  • 2006, Doctor of Medicine, Rush University, Chicago, Illinois
  • 2001, Bachelor of Science, University of Illinois, Urbana-Champaign, Illinois
Fellowship
  • 2012, Fellowship, Hematology and Oncology, University Hospitals, Cleveland, Ohio
Residency
  • 2009, Residency, Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois
Internship

  • 2007, Internship, Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois

Professional Experience
  • 2022-present, Associate Professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope, Duarte, California
Publications

View all publications

  • Nachar VR, Perissinotti AJ, Marini BL, Karimi YH, Phillips TJ. COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell  on-Hodgkin lymphoma. Ann Hematol. 2023 Sep;102(9):2635-2637. doi: 10.1007/s00277-023-05315-1. Epub 2023 Jun 9. PubMed PMID: 37294440; PubMed Central PMCID: PMC10250838.

  • Phillips TJ, Bond D, Takiar R, Kump K, Kandarpa M, Boonstra P, Mayer TL, Nachar V, Wilcox RA, Carty SA, Karimi YH, Nikolovska-Coleska Z, Kaminski MS, Herrera AF, Maddocks K, Popplewell L, Danilov AV. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. 2023 Aug 22;7(16):4518-4527. doi: 10.1182/bloodadvances.2023009992. PubMed PMID: 37013954; PubMed Central PMCID: PMC10425679.

  • Le K, Sun J, Ghaemmaghami J, Smith MR, Ip WKE, Phillips T, Gupta M. Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity. Blood Adv. 2023 Aug 8;7(15):3952-3967. doi: 10.1182/bloodadvances.2022008722. PubMed PMID: 36630565; PubMed Central PMCID: PMC10410136.

  • Lam V, Roleder C, Liu T, Bruss N, Best S, Wang X, Phillips T, Shouse G, Berger AJ, Alinari L, Wang L, Siddiqi T, Pennock ND, Danilov AV. T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia. Mol Cancer Ther. 2023 Jul 6;. doi: 10.1158/1535-7163.MCT-22-0762. [Epub ahead of print] PubMed PMID: 37420267.

  • Takiar R, Phillips TJ. Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma. Blood Adv. 2023 Jun 27;7(12):2912-2916. doi: 10.1182/bloodadvances.2022007537. PubMed PMID: 36812691; PubMed Central PMCID: PMC10285534.

  • Burke JM, Liu N, Yu KS, Fanale MA, Surinach A, Flores C, Lisano J, Phillips T. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. Oncologist. 2023 Jun 2;28(6):520-530. doi: 10.1093/oncolo/oyad068. PubMed PMID: 36971492; PubMed Central PMCID: PMC10243782.

  • Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-005584. PubMed PMID: 37385724; PubMed Central PMCID: PMC10314623.

  • Gordon MJ, Bond DA, Kittai AS, Amirmokhtari N, Steinbrunner A, Huffman A, Orellana-Noia V, Shouse G, Cohen JB, Phillips T, Danilov AV. TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma. Haematologica. 2023 May 25;. doi: 10.3324/haematol.2023.283074. [Epub ahead of print] PubMed PMID: 37226703.

  • Phillips T, Migliaccio-Walle K, Yu KS, Bloudek B, Liu N, Fanale M, Burke JM. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 May;64(5):1017-1025. doi: 10.1080/10428194.2023.2193854. Epub 2023 Apr 19. PubMed PMID: 37074674.

  • Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. PubMed PMID: 36548927; PubMed Central PMCID: PMC10115554.

  • Paun, O., Phillips, T., Fu, P., Novoa, R.A., Honda, K.S., Lu, K.Q., & Lazarus, H.M. Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. Biology of blood and marrow transplantation: Journal of the American Society for Blood and Marrow Transplantation 19(8): 1204-9, 08/2013. PM23688396.
  • Megahed, A., Faulhaber, P., Phillips, T., & Koon, H. Delayed response in ipilimumab therapy. J Community Support Oncol 12(3): 109-10, 01/2014. PM24971417.
  • Phillips, T., Devata, S., Wilcox, R.A. Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer 4: 95, 01/2016. PM28031823/PMC5170899.
  • Martin, P., Maddocks, K., Leonard, J.P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., Spurgeon, S., Kozin, E., Noto, K., Chen, Z., Jurczak, W., Auer, R., Chmielowska, E., Stilgenbauer, S., Bloehdorn, J., Portell, C., Williams, M.E., Dreyling, M., Barr, P.M., Chen-Kiang, S., DiLiberto, M., Furman, R.R., & Blum, K.A. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127(12): 1559-1563, 03/2016. PM26764355.
  • Chen, R.W., Li, H., Bernstein, S.H., Kahwash, S., Rimsza, L.M., Forman, S.J., Constine, L., Shea, T.C., Cashen, A.F., Blum, K.A., Fenske, T.S., Barr, P.M., Phillips, T., Leblanc, M., Fisher, R.I., Cheson, B.D., Smith, S.M., Faham, M., Wilkins, J., Leonard, J.P., Kahl, B.S., & Friedberg, J.W. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Epub 2016 Dec 19. Br J Haematol 176(5): 759-769, 12/2016. PM27992063.
  • Murga-Zamalloa, C., Polk, A., Hanel, W., Chowdhury, P., Brown, N., Hristov, A.C., Bailey, N.G., Wang, T., Phillips, T., Devata, S., Poonnen, P., Gomez-Gelvez, J., Inamdar, K.V., Wilcox, R.A. Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget 8 (70): 114474-114480, 01/2017. PM29383095/PMC5777707.
  • Dolan, J.M., DeGraft-Johnson, A., McDonald, N., Ward, B.B., Phillips, T.J. & Munz, S.M. Maxillary and Mandibular Non-Hodgkin Lymphoma with Concurrent Periapical Endodontic Disease: Diagnosis and Management. J Endod 43(10): 1744-1749, 10/2017. PM28734649.
  • Neumann, D.R., Marini, B.L., Phillips, T.J., Wilcox, R.A., Mayer, T.L., Brown, A. & Perissinotti, A.J. Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. Leuk Lymphoma 6: 1-10, 11/2017. PM29105525.
  • Wang, M., Schuster, S.J., Phillips, T., Lossos, I.S., Goy, A., Rule, S., Hamadani, M., Ghosh, N., Reeder, C.B., Barnett, E., Bravo, M.C. & Martin, P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 10(1): 171, 11/2017. PM29096668.
  • Boonstra, P.S., Polk, A., Brown, N., Hristov, A.C., Bailey, N.G., Kaminski, M.S., Phillips, T., Devata, S., Mayer, T., & Wilcox, R.A. Epub 2017 Sep 25.: A Single Center Phase II Study of Ixazomib in Patients with Relapsed or Refractory Cutaneous or Peripheral T-cell Lymphomas. Am J Hematol 92(12): 1287-1294, 12/2017. PM28842936/PMC6116510.
  • Phillips, T.J., Forero-Torres, A., Sher, T., Diefenbach, C.S., Johnston, P., Talpaz, M., Pulini, J., Zhou, L., Scherle, P., Chen, X., & Barr, P.M. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood 132(3): 293-306, 01/2018. PM29695516/PMC6107856.
  • Zhang, J.Y., Briski, R., Devata, S., Kaminski, M.S., Phillips, T.J., Mayer, T.L., Bailey, N.G., & Wilcox, R.A. Survival Following Salvage Therapy for Primary Refractory Peripheral T-Cell Lymphomas (PTCL). Epub 2017 Dec 18 Am J Hematol 93(3): 394-400, 03/2018. PM29194714/PMC5803354.
  • Wang, F., Gatica, D., Ying, Z.X., Peterson, L.F., Kim, P., Bernard, D., Saiya-Cork, K., Wang, S., Kaminski, M.S., Chang, A.E., Phillips, T., Klionsky, D.J., & Malek, S.N. Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR. J Clin Invest 130: 1626-1640, 01/2019. PM30720463/PMC6436860.
  • Geer, M., Roberts, E., Shango, M., Till, B.G., Smith, S.D., Abbas, H., Hill, B.T., Kaplan, J., Barr, P.M., Caimi, P., Stephens, D.M., Lin, E., Herrera, A.F., Rosenbaum, E., Amengual, J.E., Boonstra, P.S., Devata, S., Wilcox, R.A., Kaminski, M.S., & Phillips, T.J. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Epub ahead of print 2019 May 1. doi: 10.1111/bjh.15923 Br J Haematol: 01/2019. (In Press) PM31044423.
  • Matasar, M.J., Luminari, S., Barr, P.M., Barta, S.K., Danilov, A.V., Hill, B.T., Phillips, T.J., Jerkeman, M., Magagnoli, M., Nastoupil, L.J., Persky, D.O., & Okosun, J. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist 130: 1626-1640, 01/2019. PM31346132.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.